1. Search Result
Search Result
Results for "

Mitochondrial Metabolism

" in MCE Product Catalog:

23

Inhibitors & Agonists

4

Screening Libraries

1

Peptides

4

Natural
Products

2

Isotope-Labeled Compounds

Cat. No. Product Name Target Research Areas
  • HY-B2246
    L-Carnitine hydrochloride

    (R)-Carnitine hydrochloride; Levocarnitine hydrochloride

    Endogenous Metabolite Metabolic Disease
    L-Carnitine hydrochloride ((R)-Carnitine hydrochloride), a highly polar, small zwitterion, is an essential co-factor for the mitochondrial β-oxidation pathway. L-Carnitine hydrochloride functions to transport long chain fatty acyl-CoAs into the mitochondria for degradation by β-oxidation. L-Carnitine hydrochloride is an antioxidant. L-Carnitine hydrochloride can ameliorate metabolic imbalances in many inborn errors of metabolism.
  • HY-15453
    Devimistat

    CPI-613

    Apoptosis Mitochondrial Metabolism Cancer
    Devimistat (CPI-613) is a mitochondrial metabolism inhibitor. Devimistat is a lipoic acid antagonist that abrogates mitochondrial energy metabolism to induce apoptosis in various cancer cells.
  • HY-P0245
    Speract

    Mitochondrial Metabolism Metabolic Disease
    Speract, a sea urchin egg peptide that regulates sperm motility, also stimulates sperm mitochondrial metabolism.
  • HY-N4104
    Agaric acid

    Agaricinic Acid

    Mitochondrial Metabolism Metabolic Disease
    Agaric acid (Agaricinic Acid) is obtained from various plants of the fungous tribe, i.e. Polyporus officinalis and Polyporus igniarius. Agaric acid induces mitochondrial permeability transition through its interaction with the adenine nucleotide translocase. Agaric acid promotes efflux of accumulated Ca 2+, collapse of transmembrane potential, and mitochondrial swelling. Agaric acid is used to regulate lipid metabolism.
  • HY-B0486
    Lonidamine

    AF-1890; Diclondazolic Acid; DICA

    Hexokinase Mitochondrial Metabolism Apoptosis Parasite Cancer Inflammation/Immunology
    Lonidamine (AF-1890) is a hexokinase and mitochondrial pyruvate carrier inhibitor (Ki: 2.5 μM). Lonidamine also inhibits aerobic glycolysis in cancer cells. Lonidamine can be used in the research of mitochondrial metabolism and inflammation, such as pulmonary fibrosis.
  • HY-W012572
    D-Histidine

    Mitochondrial Metabolism Metabolic Disease
    D-Histidine is an enantiomer of L-histidine (HY-N0832). L-Histidine is an essential amino acid for infants. L-Histidine is an inhibitor of mitochondrial glutamine transport.
  • HY-135425
    10,12-Tricosadiynoic acid

    Acyltransferase Metabolic Disease
    10,12-Tricosadiynoic acid is a highly specific, selective, high affinity and orally active acyl-CoA oxidase-1 (ACOX1) inhibitor. 10,12-Tricosadiynoic acid can treat high fat diet- or obesity-induced metabolic diseases by improving mitochondrial lipid and ROS metabolism.
  • HY-139577
    Ninerafaxstat

    Mitochondrial Metabolism Cancer
    Ninerafaxstat hifts cellular metabolism from fatty acid oxidation to glucose oxidation.Ninerafaxstat decreases fatty acid oxidation and improve overall mitochondrial respiration.Ninerafaxstat inhibit the growth and proliferation of cancer cells.
  • HY-B0158
    Cytidine

    Cytosine β-D-riboside; Cytosine-1-β-D-ribofuranoside

    Nucleoside Antimetabolite/Analog Endogenous Metabolite Neurological Disease
    Cytidine is a pyrimidine nucleoside and acts as a component of RNA. Cytidine is a precursor of uridine. Cytidine controls neuronal-glial glutamate cycling, affecting cerebral phospholipid metabolism, catecholamine synthesis, and mitochondrial function.
  • HY-B0399
    L-Carnitine

    (R)-Carnitine; Levocarnitine

    Endogenous Metabolite Neurological Disease Cancer
    L-Carnitine ((R)-Carnitine), a highly polar, small zwitterion, is an essential co-factor for the mitochondrial β-oxidation pathway. L-Carnitine functions to transport long chain fatty acyl-CoAs into the mitochondria for degradation by β-oxidation. L-Carnitine is an antioxidant. L-Carnitine hydrochloride can ameliorate metabolic imbalances in many inborn errors of metabolism.
  • HY-148165
    L-Cytidine

    Nucleoside Antimetabolite/Analog Neurological Disease
    L-Cytidine is an L-configurational form of Cytidine (HY-B0158). L-Cytidine is a pyrimidine nucleoside, a component of RNA. Cytidine can control the glial glutamate cycle, affect brain phospholipid metabolism, catecholamine synthesis and mitochondrial function.
  • HY-B2246S
    L-Carnitine-d9 chloride

    (R)-Carnitine-d9 chloride; Levocarnitine-d9 chloride

    Endogenous Metabolite Metabolic Disease
    L-Carnitine-d9 chloride is the deuterium labeled L-Carnitine chloride. L-Carnitine chloride, a highly polar, small zwitterion, is an essential co-factor for the mitochondrial β-oxidation pathway. L-Carnitine chloride functions to transport long chain fatty acyl-CoAs into the mitochondria for degradation by β-oxidation. L-Carnitine chloride is an antioxidant. L-Carnitine chloride can ameliorate metabolic imbalances in many inborn errors of metabolism.
  • HY-B1334
    Perhexiline

    Mitochondrial Metabolism Apoptosis Cancer Cardiovascular Disease
    Perhexiline is an orally active CPT1 and CPT2 inhibitor that reduces fatty acid metabolism. Perhexiline induces mitochondrial dysfunction and apoptosis in hepatic cells. Perhexiline can cross the blood brain barrier (BBB) and shows anti-tumor activity. Perhexiline can be used in the research of cancers, and cardiovascular disease like angina.
  • HY-B1334A
    Perhexiline maleate

    Mitochondrial Metabolism Apoptosis Cancer Cardiovascular Disease
    Perhexiline maleate is an orally active CPT1 and CPT2 inhibitor that reduces fatty acid metabolism. Perhexiline maleate induces mitochondrial dysfunction and apoptosis in hepatic cells. Perhexiline maleate can cross the blood brain barrier (BBB) and shows anti-tumor activity. Perhexiline maleate can be used in the research of cancers, and cardiovascular disease like angina.
  • HY-B0158S
    Cytidine-d2

    Cytosine β-D-riboside-d2; Cytosine-1-β-D-ribofuranoside-d2

    Nucleoside Antimetabolite/Analog Endogenous Metabolite Neurological Disease
    Cytidine-d2 (Cytosine β-D-riboside-d2) is the deuterium labeled Cytidine. Cytidine is a pyrimidine nucleoside and acts as a component of RNA. Cytidine is a precursor of uridine. Cytidine controls neuronal-glial glutamate cycling, affecting cerebral phospholipid metabolism, catecholamine synthesis, and mitochondrial function.
  • HY-134978
    (Rac)-SHIN2

    Others Others
    (Rac)-SHIN2 is a serine hydroxymethyltransferase (SHMT) inhibitor having 1,4-dihydropyrano[2,3-c]pyrazole structure. (Rac)-SHIN2 involves in folate or one-carbon metabolism pathways, prevents viral infection. SHMT1 and SHMT2 are the cytosolic and/or mitochondrial isoforms of serine hydroxymethyltransferase, respectively.
  • HY-113884B
    (S)-Coriolic acid

    13(S)-HODE

    PPAR Mitochondrial Metabolism Cancer Inflammation/Immunology
    (S)-Coriolic acid (13(S)-HODE), the product of 15-lipoxygenase (15-LOX) metabolism of linoleic acid, functions as the endogenous ligand to activate PPARγ. (S)-Coriolic acid is an important intracellular signal agent and is involved in cell proliferation and differentiation in various biological systems. (S)-Coriolic acid induces mitochondrial dysfunction and airway epithelial injury.
  • HY-128895
    KL1333

    Mitochondrial Metabolism Metabolic Disease
    KL1333, a derivative of β-lapachone, is an orally available NAD+ modulator. KL1333 reacts with NAD(P)H:quinone oxidoreductase 1 (NQO1) as a substrate, resulting in increases in intracellular NAD+ levels via NADH oxidation. KL1333 improves energy metabolism and mitochondrial dysfunction in MELAS fibroblasts. KL1333 protects against Cisplatin-induced ototoxicity in mouse cochlear cultures.
  • HY-136408
    Malonyl Coenzyme A lithium

    Mitochondrial Metabolism Metabolic Disease
    Malonyl Coenzyme A lithium is an inhibitor of carnitine palmitoyl transferase 1 (CPT1). High Malonyl Coenzyme A lithium concentrations suppress fatty acid oxidation, while low Malonyl Coenzyme A lithium concentrations are permissive for fat oxidation.
  • HY-N0303
    Idebenone

    Mitochondrial Metabolism Apoptosis Neurological Disease
    Idebenone, a well-appreciated mitochondrial protectant, exhibits protective efficacy against neurotoxicity and can be used for the research of Alzheimer's disease, Huntington's disease. Idebenone (oxidised form) has a dose-dependent inhibitory effect on the enzymatic metabolism of arachidonic acid in astroglial homogenates (IC50=16.65 μM). Idebenone, a coenzyme Q10 analog and an antioxidant, induces apoptotic cell death in the human dopaminergic neuroblastoma SHSY-5Y cells. Idebenone quickly crosses the blood-brain barrier.
  • HY-108022A
    MSDC-0602K

    Azemiglitazone potassium

    Insulin Receptor PPAR Metabolic Disease
    MSDC-0602K (Azemiglitazone potassium), a PPARγ-sparing thiazolidinedione (Ps-TZD), binds to PPARγ with the IC50 of 18.25 μM. MSDC-0602K modulates the mitochondrial pyruvate carrier (MPC). MSDC-0602K can be used for the research of fatty liver including dysfunctional lipid metabolism, inflammation, and insulin resistance. MSDC-0602K, an insulin sensitizer, improves insulinemia and fatty liver disease in mice, alone and in combination with Liraglutide.
  • HY-13409A
    SB 242084 dihydrochloride

    5-HT Receptor Metabolic Disease Neurological Disease
    SB 242084 dihydrochloride is a selective, competitive and high-affinity (pKi=9.0) 5-HT2C receptor antagonist (crosses the blood-brain barrier). SB 242084 dihydrochloride increases basal activity of dopaminergic neurons in the ventral tegmental area (VTA) of the midbrain and dopamine release in the vomeronasal nucleus. SB 242084 dihydrochloride also increases mitochondrial gene expression and oxidative metabolism via 5-HT2A receptor. SB 242084 dihydrochloride has good research potential in the negative symptoms of anxiety, depression and schizophrenia, as well as in acute organ damage.
  • HY-13409
    SB 242084

    5-HT Receptor Metabolic Disease Neurological Disease
    SB 242084 is a selective, competitive and high-affinity (pKi=9.0) 5-HT2C receptor antagonist (crosses the blood-brain barrier). SB 242084 increases basal activity of dopaminergic neurons in the ventral tegmental area (VTA) of the midbrain and dopamine release in the vomeronasal nucleus. SB 242084 also increases mitochondrial gene expression and oxidative metabolism via 5-HT2A receptor. SB 242084 has good research potential in the negative symptoms of anxiety, depression and schizophrenia, as well as in acute organ damage.